Use of Lidocaine in Rapid Sequence Induction

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01238718
Recruitment Status : Completed
First Posted : November 11, 2010
Last Update Posted : August 24, 2011
Information provided by:
University of Athens

November 8, 2010
November 11, 2010
August 24, 2011
October 2008
July 2011   (Final data collection date for primary outcome measure)
BIS changes after lidocaine administration in rapid sequence induction [ Time Frame: change from baseline in BIS values during 10 minutes ]
Same as current
Complete list of historical versions of study NCT01238718 on Archive Site
  • change in blood pressure [ Time Frame: change from baseline in blood pressure during 10 minutes ]
  • change in Heart rate [ Time Frame: change from baseline in heart rate durng 10 minutes ]
Same as current
Not Provided
Not Provided
Use of Lidocaine in Rapid Sequence Induction
Impact of Lidocaine on Anesthetic Depth During Rapid Sequence Induction
Lidocaine has been shown to blunt the cardiovascular response to endotracheal intubation. The incidence of hypertension, tachycardia and dysrhythmias due to laryngoscopy may be increased in patients that receive rapid sequence induction and intubation, where opioids are spared and intravenous anesthetic agents are not titrated step by step. Our hypothesis was that lidocaine when administered intravenously in patients who undergo rapid sequence induction may not only blunt the hemodynamic response to intubation, but may also increase the anesthetic depth (as assessed by BIS), thus further reducing the possibility of hypertension, arrhythmias and also awareness.
Not Provided
Not Applicable
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Hemodynamic Response
  • Drug: Lidocaine
    lidocaine 1.5 mg/kg intravenously
  • Drug: Placebo
    normal saline
  • Active Comparator: lidocaine
    Intervention: Drug: Lidocaine
  • Placebo Comparator: normal saline
    Intervention: Drug: Placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
July 2011
July 2011   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • reason for rapid sequence induction (emergency, reflux),
  • ASA I-II,
  • no antihypertensive drugs,
  • no antiarrhythmic drugs

Exclusion Criteria :

Sexes Eligible for Study: All
20 Years to 70 Years   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
Not Provided
Not Provided
Not Provided
University of Athens, Chryssoula Staikou, 1st department of Anesthesiology, Aretaieio Hospital, University of Athens, Greece
University of Athens
Not Provided
Not Provided
University of Athens
November 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP